Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin vs Fluconazole for Invasive Candidiasis
NCT00056368Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2003
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anidulafungin in candidemia and invasive candidiasis (2 arms), sponsored by Pfizer. Primary endpoint: Global Response (Clinical and Microbiologic) at the End of Intravenous Therapy. Started Mar 2003; status: completed.
02
Drugs
anidulafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT00056368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056368.